Allogene Therapeutics appointed Zachary Roberts, its EVP of R&D and CMO, to succeed co-founder David Chang as president and CEO. Roberts will start July 1, while Chang will remain on the board after an eight-year leadership tenure at the off-the-shelf cell therapy company. The transition comes as Allogene continues to execute on its clinical and manufacturing roadmap, with CMO-level ownership suggesting continued emphasis on product development and operational execution. The management change also reflects the broader industry reality that cell therapy companies often shift leadership emphasis as programs move from development into scale and commercialization planning. For investors and partners, CEO succession can affect trial execution tempo, CMC priorities, and partnership cadence—key variables in next-stage biotech outcomes.